About the Authors

Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD(A, B)
Kalyna Z. Bezchlibnyk-Butler, BScPhm, FCSHP
J. Joel Jeffries, MB, FRCPC, DFCPA(C)


The Editors wish to acknowledge contributions from the following chapter co-editors:
Ana Aleksic, MScPharm(A) (Antipsychotic-Induced Extrapyramidal Side Effects and Their Management)
Alasdair Barr, PhD(D) (Drugs of Abuse)
Agnieszka K. Biala, MPharm, PhD(E) (Sex-Drive Depressants)
Andrius Baskys, MD, PhD(F) (Drugs for Treatment of Dementia, Pharmacogenomic Information for Common Psychotropic Drugs)
Sue Corrigan, BScPharm, ACPR, PharmD(G) (Antipsychotics)
Robert Dickey, MD, FRCPC(C) (Sex-Drive Depressants)
Lynda Eccott, BSc, MScPharm(H) (Natural Health Products)
Dean Elbe, BScPharm, PharmD, BCPP(I) (Drugs for ADHD)
Katelyn Halpape, BSP, ACPR, PharmD, BCPP(J) (Mood Stabilizers)
Gary Hasey, MD, FRCPC, MSc(K) (Repetitive Transcranial Magnetic Stimulation)
Steven Kary, BSP, ACPR(L) (Mood Stabilizers)
David D. Kim, MSc(D) (Antidepressants, Drugs of Abuse) Barry A. Martin, MD, FRCPC(C) (Electroconvulsive Therapy)
Melanie McLeod, BSP, ACPR, PharmD, BCPP(M) (Mood Stabilizers)
Reza Rafizadeh, BScPharm, RPh, ACPR, BCPP(G) (Antipsychotics, Treatment of Substance Use Disorders)
Christian G. Schütz, MD, PhD, MPH, FRCPC(N) (Treatment of Substance Use Disorders)
Jacky T. P. Siu, BScPharm, ACPR, PharmD(G) (Anxiolytics, Hypnotics/Sedatives)
Fidel Vila-Rodriguez, MD, FRCPC, FAPA(A) (Electroconvulsive Therapy)
Vivian Yih, BScPharm, PharmD(O) (Antidepressants)
Bree Zehm, PharmD(P) (Antidepressants)
Tony Zhou, PharmD(H) (Drug Interactions)

(A) Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
(B) British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada
(C) Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada
(D) Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada
(E) Department of Pediatrics, Canadian Pharmacogenomics Network for Drug Safety, University of British Columbia, Vancouver, BC, Canada
(F) Riverside Psychiatric Medical Group Memory Disorders Program, Riverside, CA, USA
(G) Lower Mainland Pharmacy Services and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
(H) Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
(I) Children's & Women's Mental Health Programs, BC Mental Health and Substance Use Services/BC Children's Hospital, Vancouver, BC, Canada
(J) College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada
(K) Departments of Psychiatry and Behavioural Neurosciences, Biomedical, Electrical and Computer Engineering, McMaster University, Hamilton, ON, Canada
(L) Saskatoon Cancer Centre, Saskatoon, SK, Canada
(M) Department of Psychiatry, Saskatchewan Health Authority, Regina, SK, Canada
(N) Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada, and Burnaby Center for Mental Health & Addiction, Burnaby, BC, Canada
(O) Fraser Health Authority Mental Health and Substance Use Tertiary Older Adult Program, Vancouver, BC, Canada
(P) Department of Pharmacy, Island Health, Victoria, BC, Canada